SCHEMBL20652758

SCHEMBL20652758

CCn1c(=O)[nH]c(=O)c2[nH]c(-c3nccnc3Cl)nc21

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA2A P29274 8/20 0.49
▸ PDE4A P27815 3/20 0.49
▸ PDE4B Q07343 3/20 0.49
▸ PDE4C Q08493 3/20 0.49
▸ PDE4D Q08499 3/20 0.49
▸ ADORA2B P29275 8/20 0.47
▸ ADORA1 P30542 4/20 0.42
▸ HSD17B10 Q99714 3/20 0.39
▸ HPGD P15428 2/20 0.39
▸ ADORA3 P0DMS8 2/20 0.39
▸ BLM P54132 1/20 0.39
▸ PDE3A Q14432 1/20 0.39
▸ KDM4E B2RXH2 2/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ THPO P40225 1/20 0.38
▸ PMP22 Q01453 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20652969 0.83 KMT2A (0.47) ADORA2AADORA2BADORA1HSD17B10KDM4E
SCHEMBL20652782 0.80 ADORA2A (0.34) ADORA2AADORA2BADORA1HSD17B10HPGD
SCHEMBL22109849 0.77 ADORA2A (0.49) ADORA2APDE4APDE4BPDE4CPDE4D
SCHEMBL22105782 0.76 ADORA2B (0.54) ADORA2APDE4APDE4BPDE4CPDE4D
SCHEMBL22105718 0.73 ADORA2B (0.48) ADORA2APDE4APDE4BPDE4CPDE4D
SCHEMBL7866617 0.72 ADORA2B (0.62) ADORA2APDE4APDE4BPDE4CPDE4D
SCHEMBL20652759 0.71 MEN1 (0.57) HSD17B10HPGDBLMKDM4EALDH1A1
SCHEMBL10963141 0.70 ADORA2A (0.55) ADORA2APDE4APDE4BPDE4CPDE4D
SCHEMBL12233275 0.70 ADORA2A (0.55) ADORA2APDE4APDE4BPDE4CPDE4D
SCHEMBL22105773 0.70 ADORA2B (0.45) ADORA2APDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3652176-B1 SUBSTITUTED XANTHINE DERIVATIVES BOEHRINGER INGELHEIM INT (DE) 2021-12-15 — — EP disclosed
US-10329292-B2 Substituted xanthine derivatives BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2019-06-25 — — US disclosed
WO-2019011802-A1 NOVEL SUBSTITUTED XANTHINE DERIVATIVES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2019-01-17 — — WO disclosed
US-20190016722-A1 NOVEL SUBSTITUTED XANTHINE DERIVATIVES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2019-01-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10329292-B2 Substituted xanthine derivatives TRPC5, TRPV1, TRPC4 ADORA2A 274/4885PDE4A 517/4885PDE4B 525/4885
US-20190016722-A1 NOVEL SUBSTITUTED XANTHINE DERIVATIVES TRPC5, TRPC4, TRPV1 ADORA2A 311/4885PDE4A 375/4885PDE4B 376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback